At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular dis ...

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

Dow, S&P 500, and Nasdaq futures are rising in premarket trading Wednesday as the stock market braces for minutes from the Fed's monetary policy meeting.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The millennial-focused digital health company Hims & Hers (HIMS) has donated $1 million to President-elect Donald Trump’s ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Bernstein upgraded Novo Nordisk (NYSE:NVO) to “Market Perform” with a stock price of $84.86. The company’s stock shows slight ...

Kuykendall has been in his current role since July 2022. Interesting fact: He has worked with Novo Nordisk for more than 18 ...